Benign Growth For Beam Therapeutics Inc. (NASDAQ:BEAM) Underpins Stock's 30% Plummet
Beam Therapeutics Inc. (NASDAQ:BEAM) shareholders won't be pleased to see that the share price has had a very rough month, dropping 30% and undoing the prior period's positive performance. Instead
Simply Wall StApr 24 08:51 ET
Expert Ratings For Beam Therapeutics
In the latest quarter, 5 analysts provided ratings for Beam Therapeutics (NASDAQ:BEAM), showcasing a mix of bullish and bearish perspectives.In the table below, you'll find a summary of their recent r
BenzingaApr 23 14:00 ET
Express News | Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $57 Price Target
Moomoo 24/7Apr 23 12:32 ET
Beam Therapeutics: A Strong Buy on Gene Editing Advancements and Strategic Growth Potential
TipRanksApr 23 07:16 ET
Beam Therapeutics Stock (NASDAQ:BEAM): Investing in Cutting-Edge Gene Editing
TipRanksApr 22 16:37 ET
Popular Crypto Trader Shares 2024 Predictions For These Three Altcoins
Popular pseudonymous crypto analyst Altcoin Sherpa on Friday shared his insights on three altcoins: Beam (CRYPTO: BEAM), Arbitrum (CRYPTO: ARB), and Render (CRYPTO: RNDR). BEAM: A Bullish Bet On Crypt
BenzingaApr 12 13:55 ET
Beam Therapeutics (NASDAQ:BEAM) Is In A Good Position To Deliver On Growth Plans
Yahoo FinanceApr 11 07:14 ET
Beam Therapeutics Insider Sold Shares Worth $734,805, According to a Recent SEC Filing
Amy Simon, Chief Medical Officer, on April 01, 2024, sold 23,687 shares in Beam Therapeutics (BEAM) for $734,805. Following the Form 4 filing with the SEC, Simon has control over a total of 70,060 sha
MT NewswiresApr 4 10:15 ET
Beam Therapeutics: A Buy Rating Amidst Gene Editing Industry Developments
TipRanksApr 2 19:25 ET
Form 144 | Beam Therapeutics(BEAM.US) Officer Proposes to Sell 504.85K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 2, $Beam Therapeutics(BEAM.US)$ Officer AMY SIMON intends to sell 16,530 shares of its common stock on Apr 2, with a total market value of approximately $504.85K. AMY SIM
moomoo NewsApr 2 16:28 ET
Express News | Beam Therapeutics Shares Are Trading Lower After Verve Therapeutics Paused Enrollment in Its Heart-1 Clinical Trial. Verve and Beam Previously Entered a License Agreement for Access to Beam's Base Editing, Gene Editing, and Delivery Technologies
Moomoo 24/7Apr 2 15:30 ET
Gene Therapy Side Effects: Verve Therapeutics Halts Enrollment Of Lead Gene Therapy Trial In Patients With Bad Cholesterol
Verve Therapeutics Inc (NASDAQ:VERV) announced an update from the Heart-1 Phase 1b trial of VERVE-101.VERVE-101 is being evaluated in patients with a genetic condition that leads to high cholesterol l
BenzingaApr 2 12:19 ET
Biotech Roundtable: Who Will Bring the Next CRISPR Drug to Market?
Seeking AlphaApr 2 11:36 ET
Verve Drops After Pausing Enrollments in Trial for Lead Asset
Seeking AlphaApr 2 07:34 ET
Beam Therapeutics(BEAM.US) Officer Sells US$2.03 Million in Common Stock
$Beam Therapeutics(BEAM.US)$ Officer Evans John M. sold 60,000 shares of Common Stock on Mar 28, 2024 at an average price of $33.8567 for a total value of $2.03 million.Source: Announcement What is st
moomoo NewsApr 1 16:51 ET
Here's Why We're Not Too Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring reve
Simply Wall StApr 1 08:14 ET
Is Beam Therapeutics Stock (NASDAQ:BEAM) Too Late to the Game?
TipRanksMar 30 15:48 ET
Form 144 | Beam Therapeutics(BEAM.US) Officer Proposes to Sell 2.03 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Mar 28, $Beam Therapeutics(BEAM.US)$ Officer JOHN M EVANS intends to sell 60,000 shares of its common stock on Mar 28, with a total market value of approximately $2.03 million.
moomoo NewsMar 28 18:16 ET
Expert Outlook: Beam Therapeutics Through The Eyes Of 4 Analysts
Expert Outlook: Beam Therapeutics Through The Eyes Of 4 Analysts
BenzingaMar 27 11:01 ET
Beam Therapeutics Is Maintained at Outperform by BMO Capital
Beam Therapeutics Is Maintained at Outperform by BMO Capital
Dow JonesMar 27 10:22 ET
No Data
No Data